This compound is a key chiral intermediate in the pharmaceutical industry, specifically used in the multi-step synthesis of triazole-based antifungal drugs such as posaconazole. It features a tetrahydrofuran ring with a 2,4-difluorophenyl substituent and a 1,2,4-triazol-1-ylmethyl group, along with a 4-chlorobenzenesulfonate ester for activation in subsequent reactions. The resulting antifungal agents inhibit lanosterol 14α-demethylase, an enzyme critical for ergosterol biosynthesis in fungal cell membranes, thereby treating systemic and invasive fungal infections like candidiasis and aspergillosis, particularly in immunocompromised patients. Its stereospecific structure ensures the correct configuration in the final drug, enhancing potency, bioavailability, and resistance to metabolism. Current research focuses on its role in developing next-generation antifungals to combat emerging drug-resistant strains.